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Anemia during pregnancy, characterized by hemoglobin (Hb) less than 110g/l, is a specific risk factor for adverse maternal and perinatal outcomes in developing countries. The objective of this study was to determine the effectiveness of daily antenatal supplementation with the multiple micronutrients (MMN) compared to folic acid (FA) on the occurrence of anemia among pregnant women and their infants' health in a high altitude area. A non-randomisedstudy was carried out in two rural counties in Tibet from 2007 to 2012. 1149 eligible pregnant women were allocated daily supplementation with FA in one county and MMN containing a recommended allowance of 23 vitamins and minerals in another county starting ≤ 24 weeks of gestation and continuing until delivery. Compared to the FA group, the prenatal supplementation with MMN was significantly associated with reduced odds of anemia in the third trimester. This was demonstrated in the primary outcome, with an adjusted odds ratio (AOR) of 0.63, 95% confidence interval (CI): 0.45, 0.88 and P=0.007 and also reduced odds of preterm delivery (AOR: 0.31, 95% CI: 0.15, 0.61; P=0.001). There was no difference between the MMN and FA groups in mean birthweight (adjusted mean difference: 36.78, 95% CI: -19.42, 92.98 g; P=0.200) whereas the MMN supplementation significantly reduced the odds of low birthweight (LBW) babies (AOR: 0.58, 95% CI: 0.36, 0.91; P=0.019). In conclusion, the antenatal MMN supplementation in rural Tibet is associated with a reduction of maternal anemia in the third trimester, and may potentially decrease the risk of preterm delivery and LBW babies.


Anemia during pregnancy is a considerable health problem around the world and iron deficiency is the most common cause of anemia ADDIN EN.CITE (; ). Globally, the prevalence of anemia in pregnant women has decreased since 1995, but in 2011, 38% of pregnant women still suffered from anemia ADDIN EN.CITE (). In 2012, the prevalence of anemia during pregnancy in China was 17.2%(), however, the prevalence of anemia amongst pregnant women strongly varies by region and women’s gestational age. The China National Nutrition and Health Survey showed that the prevalence of anemia was 20% amongst pregnant women in poor rural areas ADDIN EN.CITE (). A non-randomisedstudy in south China indicated that about 70% of pregnant women had iron-deficiency anemia(). There is very limited information on anemia status of Tibetan pregnant women. Our previous hospital-based study in Lhasa showed that Tibetan pregnant women had lower hemoglobin (Hb) levels than non-Tibetan women throughout the entire pregnancy, averaging 126.6 g/l for Tibetans and 134.6 g/l for non-Tibetans ADDIN EN.CITE (). The percentage of women with Hb <110 g/l was 18.5% before correction for altitudes and 71.2% after correction for altitudes(). Another population-based study showed that the prevalence of anemia in pregnant women during the 1st, 2nd and 3rd trimester in rural Tibet was 79.5%, 86.1% and 87.3%, respectively ADDIN EN.CITE (). These findings suggested that Tibetan women were more likely to be anemic during pregnancy, compared to those in other region in China. 
Anemia during pregnancy is associated with adverse birth outcomes and has long-term effects. Anemia in the third trimester of pregnancy increases the incidence of low birthweight (LBW) and preterm birth ADDIN EN.CITE (; ). Hb reduction during pregnancy is associated with small for gestational age (SGA) births, placental weight and placental ratio ADDIN EN.CITE (; ; ). LBW babies are at higher risk of morbidity and mortality, and of adverse physical development in childhood compared to those of normal birthweight  ADDIN EN.CITE (; ). Anemia during pregnancy might have long-term adverse effects on younger children and a study indicated that iron-deficiency anemia in the third trimester was associated with worse mental development of rural Chinese young children ADDIN EN.CITE (). 
Tibet is located in the Qinghai-Tibet plateau, where more than 45% of areas are above the altitude of 4000 meters(). Hypoxia at high altitude significantly increases Hb(). However, the relationship between high altitude and Hb is less clear for those adapted to high altitudes, such as Tibetans (; ). Thus, anemic status and its adverse effects during pregnancy amongst Tibetans require further investigation. Previous cross-sectional surveys showed that the nutritional status of women and children in Tibet was worse than that in any other region in China ADDIN EN.CITE (; ; ; ; ). The LBW rate was 10.5% in rural Tibet, higher than that in other regions in China (4.6%) ADDIN EN.CITE (; ). However, there is a lack of follow-up studies on anemia and LBW among the pregnant Tibetan women.
Deficiencies in micronutrients during pregnancy are common in developing countries and have been associated with maternal anemia and adverse birth outcomes. These deficiencies may be exacerbated during pregnancy because of increased requirements for the growing fetus, placenta and maternal tissues(). Globally, anemia due to iron deficiency is one of the most prevalent micronutrient deficiencies. Therefore, preventive measures are needed to reduce and control anemia during pregnancy. Some preventative measures during pregnancy that are recommended include the fortification of principal foods with iron, the increase of health and nutritional awareness, and the improvement in sanitation. However, the most direct way to improve iron status and reduce the occurrence of anemia is suggested to be antenatal supplementation with iron-containing micronutrients ADDIN EN.CITE (; ; ). A systematic review and meta-analysis including 48 randomized trials (27 in high income countries and 21 in low or middle income countries; the dosage of iron ranging from 10 to 240 mg daily and duration of supplementation varied from 7 to 30 weeks during pregnancy) and 44 cohort studies (22 each from high income and low or middle income countries, respectively) was conducted to assess prenatal iron supplements ADDIN EN.CITE (). The review showed that iron use during pregnancy increased maternal mean Hb level by 4.59g/l and in turn reduced the risk of anemia, iron deficiency, iron deficiency anemia and LBW. This effect was particularly strong amongst pregnant women with anemic status at baseline or those from countries with low or middle income ADDIN EN.CITE (). Thus, this study suggested that the effects of micronutrient supplements containing iron during pregnancy might vary with region, population, and anemic status at the beginning of intervention. 
Tibet is a very specific setting characterized with high altitudes and hypoxia, and the effects of iron supplementation during pregnancy at high altitudes on maternal Hb, anemia, and birth outcomes remain unknown. Therefore, we conducted a non-randomisedstudy in rural Tibet to assess whether the positive impact of MMN supplementation containing iron during pregnancy on maternal anemia and adverse birth outcomes such as LBW and preterm delivery.

Methods
Study design and population
A non-randomisedstudy was conducted in the two rural counties (Dazi and Qushui), in Lhasa, located in the middle of Tibet. The mean altitude of two counties is 3706 meters above sea level. Lhasa area is one of main habitats of Tibetans.
    This study was approved by the Ethics Committee in Medical Research, Xi’an Jiaotong University (No 20070712), and registered in the Chinese Clinical Trial Registry (Registration number: ChiCTR-PNRC-09000597). 
The study sample consisted of the pregnant women in the two counties that met the study selection criteria (Figure 1). The women having less than or equal to 24 weeks of gestation were invited to participate in the study and had to provide the signed informed consent. The women were excluded from the study if they already took iron, FA, and other micronutrient supplements for more than two weeks, or had other serious illnesses. The eligible pregnant women from Dazi took MMN whereas those from Qushui took FA. Randomization was not implemented for the reasons of cultural and religious sensitivity in the study population.  FA is the standard prenatal supplementation recommended by the National Health and Family Planning Commission of China, so FA was used as the control(). All participants were required to take the supplements from the enrollment until delivery. The sample size considerations were based on a survey in rural Lhasa areas. The anemia prevalence of pregnant women in the third trimester in rural Lhasa is 75.9% (adjusted by altitude) ADDIN EN.CITE (). Taking MMN supplements during pregnancy was assumed to reduce anemia prevalence by 11% compared to FA ADDIN EN.CITE (). Using α=0.05, power =80%, 920 subjects were required. A total of 1100 pregnant women were required after accounting for ~15% dropout / loss-to-follow up.

Enrollment and pregnancy surveillance procedures
At the outset of this study, the trained village doctors and social workers conducted a survey of all women of reproductive age living in the village to identify those who were likely to become pregnant. The village doctors visited these women every month and asked them the date of their last menstrual period (LMP). The women whose periods were delayed by more than five days were given urine pregnancy tests, and confirmed pregnancies were reported to the maternal and child health care (MCH) workers in the township hospitals of the studied counties. The informed consent was obtained from all participants.
Newly identified pregnant women were interviewed to record their socio-demographic status and menstrual, reproductive and medical histories. Recruited pregnant women received three free antenatal care checks at enrollment, 28 and 32 weeks of gestation, respectively, at which they were given physical examination and asked about pregnancy complications. All the information collected during the pregnancy until the sixth week after delivery follow-up visit was recorded in the Pregnancy Care Record Book, which served both as a clinical record and data capture instrument.

Micronutrient Supplements
In this study, the two kinds of the supplements were used, MMN and FA. The MMN supplement (Materna/tablet, Wyeth Pharmaceutical Co., Ltd (China), Suzhou, China) consisted of the following components (per tablet): 450 µg vitamin A, 900 µg β-carotene, 6.25 µg vitamin D, 30 mg vitamin E, 3 mg vitamin B1, 3.4 mg vitamin B2, 10 mg vitamin B6, 12 µg  vitamin B12, 100 mg vitamin C, 30 mcg biotin, 1 mg folic acid, 20 mg nicotinamide, 10 mg pantothenic acid, 150 µg iodine, 25 µg molybdenum, 250 mg calcium, 25 mg zinc, 60 mg iron, 2.0 mg copper, 25.0 µg chromium, 5 mg manganese, 50 mg magnesium, and 25.0 µg selenium. The folate-only supplement (Scrianen/tablet, Peking University Pharmaceutical Co., Ltd, Beijing, China) contained 0.4 mg of FA per tablet. All micronutrient supplements were commercially available at the time of the study.
At enrollment, each woman received 30 tablets with instructions to take one tablet daily, preferably after meals and at the same time every day. Either the township MCH workers or the village doctors visited the women every month to provide supplements and to retrieve the used empty bottles and record the number of remaining tablets.

Data Collection
Maternal Hb during pregnancy was tested from the capillary blood collected at enrollment (≤ 24 weeks of gestation), 28 and 32 weeks of gestation, respectively. HemoCue (Ängelholm Sweden) portable spectrophotometers were used to assay Hb levels. The method of American Centers for Disease Control and Prevention (CDC) was used in this study to adjust Hb levels based on altitude for estimating the anemia prevalence. The adjusted formula is expressed as △Hb=-0.032× (Alt×3.3) +0.022× (Alt×3.3)2, where Alt refers to the altitude (km) of the village where the participant lived (). Participants whose adjusted Hb level was less than 110 g/l were considered anemic ADDIN EN.CITE (; ). 
Birthweight and length were measured by the hospital nurses within one hour of a child’s delivery. Birthweight was measured using an electronic scale (Type BD-585 TANITA Corporation, Ltd, Guangdong Province, China) with precision to the nearest 10 g. For home births (11% of all births), the township MCH workers visited the women at home within 72 hours of delivery to measure the birth anthropometry and collect the delivery information. LBW was defined as birthweight less than 2500 g(). Birth length was measured to the nearest 1 mm using a portable measuring board with a fixed head piece.
Gestational age at birth was calculated as completed days based on the first day of the LMP, which was obtained from the baseline interview. Spontaneous abortion was defined as the spontaneous end of confirmed pregnancy before 28 weeks of gestational age. Preterm delivery was defined as delivery at less than 37 weeks of gestational age. A stillbirth is defined as the spontaneous death of a fetus after 28 weeks gestation but before delivery of the baby’s head. Neonatal deaths were defined as deaths amongst live-born infants occurring within 28 days of delivery. Early neonatal death was defined as the death within 7 days after birth. Late neonatal death referred to death between 8 and 28 days after birth. We also reported perinatal mortality, which included both stillbirths and early neonatal deaths. 

Statistical Analysis
 A wealth index was constructed from an inventory of 6 household assets (including the following family belongings: motorcycles, automobiles, cattle, goats, chickens or ducks, televisions) using a principal component analysis method ADDIN EN.CITE (). The compliance rate was determined by dividing the number of actual supplements consumed by the number of supplements expected to be consumed. In the analysis, we only included singleton pregnancy to avoid the possible contamination effect on anemia and birth outcomes because the multiple pregnancies are more vulnerable to those outcomes.
To address the possible imbalance in the participants’ characteristics between the two treatment groups due to the non-randomized design of this study, a propensity score approach was used. We calculated the propensity score (a predicted probability of woman being in Dazi county) for each woman using a logistic regression model based on 14 pre-specified baseline characteristics (except Hb level adjusted by altitude) as listed in Table 2 and used this score as a control variable in the covariate adjusted analysis of the outcome variables().
The primary outcome was analyzed using a generalized estimating equation (GEE) model with treatment, time at measurement, interaction between treatment and time as fixed effects, and the propensity score and Hb level (adjusted by altitude) at baseline as covariates. Odds Ratio (OR), Adjusted Odds Ratio (AOR) and its 95% confidence interval (CI) for having anemia during prenatal care between two treatment groups were derived from the GEE model. Other outcome variables were analyzed similarly using a GEE model. For GEE model analysis of the continuous outcome such as Hb level, weeks of gestation at birth and birthweight, normal distribution and identity link functions were used. For GEE analysis of the binary outcomes such as anemia, preterm delivery, LBW, and mortality outcomes, binomial distribution and logit link functions were used. An exchangeable covariance structure was used for all GEE models. In addition, the two-sample t-test or Wilcoxon rank test was used to assess statistical differences in continuous variables between the two supplementation groups. P-value < 0.05 was considered statistically significant. All analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC, USA).

 Results
Study sample and characteristics
Figure 1 shows the flowchart of participants in this study. The enrollment began on October 26, 2007 and continued until May 4, 2011. The last baby was born on December 12, 2011, and all follow-up stopped on March 6, 2012. Over a 4.5 year period, there were 2821 confirmed pregnant women who lived in the two rural counties of Qushu and Dazi in Lhasa. Amongst them, 568 pregnant women refused to participate and 1104 women were excluded from the study as per the exclusion criteria. Thus, in total, 1149 pregnant women were enrolled in the study. There were 1013 singleton pregnant women in the third trimester available for analysis. The birthweights were not measured for 13 stillbirths and the birthweight data for 5 live births were missed. Therefore, the birthweights of 1021 singleton live births were available for analysis.
    The two counties, Qushui and Dazi, are almost identical in terms of geographical features and social status, such as population size, economic situation, medical service level, and the number of women of childbearing age (Table 1). Characteristics of the pregnant women at enrollment are shown in Table 2. All participants were Tibetan. Most were educated, but only 45.6% had completed an elementary school education. 17.4% had low body-mass index (BMI < 18.5 kg/m²) and 499 participants (43.4%) were first pregnancies.

Compliance with supplementation
The supplementation began, on average, at 15.0 (SD 5.0) weeks of gestation for both groups. The mean dosage number of supplements consumed per woman during pregnancy was 151 (SD 35) in the FA group and 148 (SD 37) in the MMN group (P=0.141). The compliance with supplementation during pregnancy was 88.2% (91.3% in the FA group and 85.7% in the MMN group; P<0.001) (Table 3). There were a few self-reported side effects, such as nausea, vomiting, headache and dizziness. The prevalence of such side effects was below 2.3% and comparable between the two treatment groups.

Comparison of maternal anemia between the supplementation groups
Blood Hb samples were available for 1037 women at enrollment, 1031 in the second prenatal care and 1013 in the third prenatal care. The blood samples were taken at a mean gestation of 15.0 (SD 5.0), 28.3 (SD 1.1) and 32.2 (SD 1.2) weeks for the first, second and third prenatal care, respectively. There was a significant increase in the Hb with MMN supplements compared to FA in the third trimester (adjusted mean difference: 5.18, 95% CI: 2.98, 7.37 g/l; P<0.001), resulting in significant reduced odds of anemia in the third trimester for these women (AOR: 0.63, 95% CI: 0.45, 0.88; P=0.007) (Table 4).

Comparison of birth outcomes between the supplementation groups
Birthweight and length samples were available for 1021 and 995 single live births, respectively. After the supplementation, the mean birthweight was 2981.9 (SD 475.7) g in the FA group, and 3006.9 (SD 387.2) g in the MMN group (adjusted mean difference: 36.78, 95% CI: -19.42, 92.98 g; P=0.200). The effect of supplementation on birth length was not statistically significant (adjusted mean difference: 0.02, 95% CI: -0.43, 0.47 cm; P=0.939). MMN resulted in a significantly longer gestation compared to that of FA (adjusted mean difference: 0.56, 95% CI: 0.33, 0.79 weeks; P<0.001). There were significant decreases in the odds of LBW and preterm delivery in the MMN group compared to the FA group (AOR: 0.58, 95% CI: 0.36, 0.91, P=0.019; AOR: 0.31, 95% CI: 0.15, 0.61, P=0.001; respectively) (Table 5). 
    MMN supplementation was associated with decreased perinatal mortality compared to FA (AOR: 0.46, 95% CI: 0.23, 0.94; P=0.034), but showed no effects on the neonatal mortality rate, early neonatal mortality rate, and stillbirth rate, though more stillbirths and neonatal death mortality were reported in the FA group (Table 6).

Discussion
To the best of our knowledge, this is the first intervention study on prenatal MMN supplementation on maternal anemia and adverse birth outcomes amongst Tibetan women living at higher altitudes. The present study found that the prenatal MMN supplementation increased Hb levels and reduced anemia significantly during the third trimester compared to the FA supplementation. Furthermore, MMN tended to increase gestational duration and decrease the risk of LBW and preterm delivery. This study provides some important evidence indicating that the MMN supplementation should be required in formulating nutrition policy on nutrient supplementation for pregnant women at high altitude areas.

Improvement of maternal anemia
In the present study, MMN or FA was administered to two groups of Tibetan pregnant women. The Hb of MMN group increased during the third trimester by 5.18 g/l at 32 weeks of gestation, significantly higher compared to the FA group. Accordingly, the supplementation with MMN decreased the risk of maternal anemia by 37% after controlling for the potential confounders compared with FA. These results further confirmed the possibility that the supplementation with iron-containing micronutrients during pregnancy improved maternal anemia, which would benefit both the mother and the child ADDIN EN.CITE (). However, the supplementation with iron-containing micronutrients for pregnant Tibetan women might be even more necessary because rural Tibetan mothers had fairly monotonous dietary patterns with traditional Tibetan foods(). Since anemia prevalence was high amongst pregnant women in rural Tibet ADDIN EN.CITE (; ), the routine supplementation of iron-containing micronutrients during pregnancy should be included in antenatal care among Tibetan women at higher altitudes. 
A cluster-randomized trial from rural western China showed that the supplementation with MMN during pregnancy could decrease the risk of maternal anemia by 28% compared to supplementation with FA ADDIN EN.CITE (). MMN in the present study decreased the risk of maternal anemia by 37%, which was a significant improvement. Although the observed difference should not be overstated due to non-randomized nature of this study, the difference might also be due to higher dose of iron in MMN supplements of the present study (60 mg iron) than that of the previous study (30 mg) ADDIN EN.CITE (), and the higher vitamin C in our MMN supplements that might enhance the absorption of iron. Moreover, a meta-analysis also indicated that the risk of maternal anemia in the third trimester could be decreased by an average of 34% after the supplementation with iron-containing micronutrients during pregnancy ADDIN EN.CITE (). Dose-response analysis showed a linear decrease in maternal anemia with higher doses of iron, up to 66 mg/day ADDIN EN.CITE (). 
The chemical composition of hemoglobin suggests that a deficiency of amino acids or iron in the maternal diet might cause anemia ADDIN EN.CITE (; ). Increased iron intake during pregnancy is necessary to meet the iron requirements of the mother and the developing fetus as well as the haemodilution which occurs in the second and third trimesters ADDIN EN.CITE (). It may suggest that the high dose of iron in micronutrients might be a key factor. Moreover, a deficiency of vitamins (vitamin B6, vitamin B12 and folate) and minerals (cobalt, magnesium, zinc and copper) may also indirectly result in anemia because they participate in one-carbon-unit metabolism and DNA synthesis ADDIN EN.CITE (; ). So, the reduction of pregnancy anemia by the MMN supplementation might be attributed partly to such vitamins and minerals. In this sense, the MMN supplements could be a priority policy recommendation during pregnancy to prevent and control maternal anemia.
   About 70% of the women in the MMN group remained anemic in the third trimester after the adjustment of altitudes by the CDC method. A trial in rural northern China found that prenatal iron supplementation (300 mg ferrous sulfate) reduced anemia, but most women still had iron deficiency ADDIN EN.CITE (). Another cluster-randomized trial conducted in rural western China found that in both iron-FA and MMN groups, more than 40% of the pregnant women were still anemic in the third trimester ADDIN EN.CITE (). Blood volume expansion during the third trimester partly accounts for the high prevalence of anemia ADDIN EN.CITE (; ). Moreover, the absorption of iron during pregnancy is a complex physiological process, in which the iron absorption decreases during the first trimester with a progressive increase in the remaining two trimesters due to the greater requirements for iron in later   pregnancy. However, the amounts that can be absorbed from the diet are less than the iron requirements in later pregnancy().
   In addition, we found that although the percentage of anemic Tibetan women during pregnancy was quite high in the present study, about half of anemic women did not exhibit typical clinical symptoms of anemia such as fatigue, reduced physiological endurance, shortness of breath and headache especially on exercise, paleness of skin, or a rapid heartbeat ADDIN EN.CITE (; ; ). Our previous study also found that prevalence of maternal anemia varied with differing correction methods for altitudes ADDIN EN.CITE (), suggesting that current available methods were probably not suitable for adjusting for Hb level according to altitude in pregnant women living in the highlands of Tibet. Better adaptation to high altitudes for Tibetans might account for this(; ), besides the unbalanced diets and poor nutritional education().

Improvement of birth outcomes
This study pointed to the possibility that the MMN supplementation during pregnancy in Tibetan women might improve certain birth outcomes. Compared to FA, the MMN supplement group had an (albeit statistically non-significant) increase in birthweight and significantly decreased the occurrence of LBW by 42%. This result implied that the MMN supplementation might positively affect Tibetan babies with lower birthweight. We also found that the MMN supplements could extend the duration of gestation by 0.56 weeks and decreased preterm birth by 69% compared to FA. However, a significant difference was not found in prevalence of the infant with SGA between MMN and FA (35.2% vs 30.1%. SGA was defined as birthweight less than 10th percentile of the gestational age-sex specific US reference for fetal growth()). Thus, it was possible that MMN reduced LBW through prolonging gestation period and thus decreasing preterm birth. 
The beneficial effects of the MMN supplementation on fetal growth could be addressed through several biological mechanisms. Deficiencies of B vitamins might cause elevated homocysteine levels, which can lead to endothelial cell dysfunction and affect placental function ADDIN EN.CITE (). Although we did not collect the data on the status of B vitamins during pregnancy in this study, our previous study found that Tibetan women with a child aged less than 24 months suffered from poor dietary intake of protein and B vitamins(). This suggested that the MMN supplements could help maintain normal homocysteine levels during pregnancy. Deficiency of some vitamins and minerals may also bring about negative effects on gene regulation and cellular metabolism ADDIN EN.CITE (; ). Moreover, the MMN supplementation could improve the nutritional and Hb status of Tibetan women because they require more micronutrients including vitamins and minerals during pregnancy(). Furthermore, MMN was found to reduce the risk of perinatal mortality by 54%, which might be a clinically important finding. The reduction of perinatal mortality could be attributed to the reduction of LBW and preterm births, which was supported by evidence of the important role of antenatal iron supplements on the reduction of LBW and preterm in the previous studies ADDIN EN.CITE (; ). However, these results should be interpreted cautiously because the present study was not powered to address this issue. These results, therefore, suggested that the MMN supplements might play a positive role in improvement of birth outcomes of Tibetan babies. 
   The response to the micronutrient supplementation during pregnancy varied by circumstances and population. A trial in China observed that the MMN supplements containing 30 mg iron significantly increased birthweight, but there was no significant reduction in LBW and early neonatal mortality. Iron-FA supplements containing 60 mg iron decreased neonatal mortality, which could be attributed to high dose of iron in the supplements  ADDIN EN.CITE (). In the present study, the MMN supplements contained 60 mg iron and no reduction of neonatal mortality in Tibetan babies was observed, but a reduction of perinatal mortality was still observed. We thought that a smaller sample size could account for this variation, but a different physiological response to MMN for Tibetan women could not be ruled out. Similar improvement of birth outcomes by MMN supplementation was also observed in a trial in Nepal. A 77 g increase in average birthweight, and a decrease in the incidence of LBW by 25% in the MMN group (15 vitamins and minerals, contained 30 mg of iron) was observed compared to the iron-FA group (contained 60 mg of iron). However, no difference was recorded for the duration of gestation or infant length ADDIN EN.CITE (). Based on the present study, the positive effects of the MMN supplementation during pregnancy on birthweight could possibly be related to addition of iron.
 A systematic review and meta-analysis of prenatal iron use confirmed that daily prenatal use of iron substantially improved birthweight in a linear dose-response fashion, probably leading to a reduction in the risk of LBW. However, the iron supplementation was not related to gestational age, preterm birth and birth length ADDIN EN.CITE (). Since the MMN supplements for pregnant women are generally a complex of MMN with vitamins and minerals including iron, FA and other B vitamins, other micronutrients besides iron in the MMN supplements could contribute to the improvement of birth outcomes(). As for the effect of the MMN supplements on the mortality of babies, the results varied by study. Our previous study ADDIN EN.CITE () did not find the reduction of neonatal mortality by the MMN supplements and the present study also found that the MMN supplements did not reduce neonatal mortality other than the reduction of perinatal death. In another randomized controlled trial in northern China ADDIN EN.CITE (), the supplementation with iron-folic acid (containing 30 mg of iron) with or without other micronutrients (15 vitamins and minerals, contained 30 mg of iron) did not affect the perinatal mortality rate compared to daily prenatal FA except that relative risks for the third-trimester maternal anemia were reduced. However, a large trial in Indonesia showed that the prenatal MMN supplementation (15 vitamins and minerals, contained 30 mg of iron), as compared to iron-folic acid (contained 30 mg of iron), reduced early infant mortality (deaths until 90 days post-partum), especially in the undernourished and anemic women ADDIN EN.CITE (). The results from the present study suggested that, for Tibetan women, the supplementation with iron-containing MMN during pregnancy tended not only to reduce the prevalence of maternal anemia, but also improve birth outcomes to some extent. However, the observed effects of the MMN supplements on mortality of Tibetan babies should be interpreted with caution.

Strengths and limitations
The lack of scientific research represented a gap in the knowledge on prenatal micronutrients supplementation and its effect on Tibetan mothers and their babies, who live in the highest altitude areas in the world. The present study is the first intervention study assessing the impact of the MMN supplements during pregnancy, compared to FA, on maternal anemia and birth outcomes in the Tibetan population. In the study, the compliance with supplementation in both arms was higher than predicted, as reflected by a mean maternal compliance rate of 88.2%. To address the possible imbalance in the participants’ characteristics between two treatment groups due to the non-randomized design of this study in the analysis, the propensity score was established and used in the GEE model for controlling for potential confounders. Therefore, the present study provides valuable evidence for Tibetan maternal and child health care policy that both Tibetan women and their babies could benefit from the MMN supplementation during pregnancy.
   We recognize several limitations in the present study. Firstly, the randomization allocation was not performed due to the difficulty of implementation because of cultural and religious sensitivity. We have tried to use the propensity score approach to control for any possible imbalance between the two groups but there still might be unobserved heterogeneities. As a result, the observed differences in the maternal anemia and birth outcomes may still be subject to possible unknown confounding factors. Secondly, we used FA as the control group because it was the standard prenatal supplements recommended by the Chinese Government during the period of this study. Thirdly, the date of LMP may be inaccurate in a small part of the pregnant women and the gestational weeks were identified based on the clinical experiences of obstetricians. Consequently, the study may underestimate the preterm rate in Tibet. 

Conclusions
This non-randomisedstudy has provided some evidence that the MMN supplements have important positive health effects for pregnant women and newborn infants, with the potential to not only reduce the prevalence of maternal anemia during pregnancy, but also improve birth outcomes to some extent in rural Tibet in high altitudes. Further randomized control trials are required to confirm such effects of this MMN formula.
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           Mean (SD) 1	3634 (47)	3768 (70)
Population 	30968	27196
Per capita GDP (RMB yuan)	9800	10000
Rate of cooperative medical service (%)	100	100
No. of women of childbearing age	8716	8239
Birth rate (‰)	14.5	15.5
No. of village clinics	11	18
No. of township hospital	5	5
No. of county hospital	1	1
No. of MCH staff	9	8
MCH, maternal and child health care.























Table 2. Baseline household and participant characteristics at enrollment1
       Variables	FA (n=465)	MMN (n=574)	P  value2
Socio-demography	　	　	
  Number of household members	5.0 (1.9)	4.6 (1.7)	< 0.001
  Per-capita income per year (RMB)			
	Median (IQR)	1500 (1400)	1667 (1747)	0.004
  Household wealth index			
                                   Median (IQR)	0.42 (1.33)	0.42 (1.40)	0.171

  Father age (years)	27.7 (4.8)	27.6 (5.0)	0.655
  Mother age (years)	25.6 (4.8)	25.4 (4.4)	0.417
Education			
  Father's education (years)	5.7 (3.7)	5.1 (3.4)	0.014
  Mother's education (years)	5.2 (3.8)	4.8 (3.5)	0.095
Reproductive history			
  Menarcheal age (years)	15.8 (1.5)	15.2 (1.5)	< 0.001
  Interval of menstruation (days)	29.0 (2.8)	28.1 (2.2)	< 0.001
  Continuous days of menstruation (days)	3.8 (1.0)	3.8 (1.0)	0.568
  Parity		1.8 (0.9)	1.8 (0.8)	0.100
  Gestational age (weeks)	15.0 (5.0)	15.0 (5.0)	0.854
Anthropometric measurements			
  Mother BMI (Kg/m²)	20.8 (2.6)	20.7 (2.2)	0.604
  Hb (g/l)	126.0 (21.4)	128.6 (21.0)	0.049
  Hb (adjusted by altitude)(g/l)	98.2 (21.4)	98.5 (21.2)	0.795
IQR, interquartile range; BMI, body mass index.
1 The data are mean (SD) unless indicated. 	




















Table 3. Number of doses and compliance of supplements consumed by supplementation groups 1
Dose and Compliance	FA (n=465)	MMN (n=574)	P value2
Supplements (capsules)			





	Consumed, mean (SD)	151 (35)	148 (37)	0.141




	Compliance, mean (SD)	91.3(10.2)	85.7 (12.9)	< 0.001
1 Compliance calculated by number of actual supplements consumed divided by number of supplements expected to be consumed.













Table 4. Comparison of anemia and Hb (g/l) of Tibetan pregnant women between by supplementation groups
　	　	　	N1	% or Mean (SD)	MMN vs FA
　	　	　			OR or Difference (95% CI)	P value	　	AOR or Difference (95% CI)3	P value
Anemia (adjusted by altitude)2	　	　		　		
	The 28.3 weeks of gestation							
		FA	461	77.4					
		MMN	570	73.5	0.81 (0.60, 1.07)	0.140		0.69 (0.50, 0.96)	0.028
	The 32.2 weeks of gestation							
		FA	451	77.8					
		MMN	562	71.9	0.74 (0.56, 0.99)	0.039		0.63 (0.45, 0.88)	0.007
Hb (adjusted by altitude)		　		　		
	The 28.3 weeks of gestation							
		FA	461	95.6 (18.8)					
		MMN	570	99.3 (18.2)	3.24 (0.88, 5.60)	0.007		4.07 (2.00, 6.15)	0.001
	The 32.2 weeks of gestation							
		FA	451	95.5 (18.2)					
		MMN	562	100.3 (18.1)	4.31 (1.69, 6.94)	0.001		5.18 (2.98, 7.37)	< 0.001
1 Data missing on the 28.3 weeks of gestation for 8 women, and the 32.2 weeks of gestation for 26 women. 
2 Anemia defined as Hb < 110 g/l.






Table 5.  Comparison of outcomes of child health between supplementation groups
Indicators	FA	　	MMN	　	MMN vs FA
	No. in group	Mean (SD) or %		No. in group	Mean (SD) or %		Difference or OR (95% CI)	P value	　	Adjusted difference or AOR(95% CI) 3	P value
Continuous outcomes 	　	　	　	　	　	　	　	　	　	　	
Birthweight (g) 1	455	2981.9 (475.7)		566	3006.9 (387.2)		26.50 (-26.50, 79.49)	0.327		36.78 (-19.42, 92.98)	0.200
Birth length (cm) 1	433	48.4 (3.6)		562	48.4 (3.2)		0.02 (-0.41, 0.44)	0.930		0.02 (-0.43, 0.47)	0.939
Gestation at birth (weeks) 2	465	39.1 (1.9)		574	39.6 (1.7)		0.49 (0.27, 0.71)	< 0.001		0.56 (0.33, 0.79)	< 0.001
Binary outcomes 											
Low birthweight (< 2500 g) 1	455	9.9		566	6.5		0.64 (0.41, 1.00) 	0.052		0.58 (0.36, 0.91) 	0.019
Preterm 2	465	7.1	　	574	2.3	　	0.30 (0.16, 0.58)	< 0.001	　	0.31 (0.15, 0.61)	0.001
1 Data analysis only includes single live births.
2 Data analysis only includes single births.













Table 6. Comparison of neonatal deaths and fetal loss between supplementation groups
Indicators		FA		MMN		Comparing MMN with FA
		No. in group	‰		No. in group	‰		OR   (95% CI)	P value	AOR (95% CI)1	P value
Neonatal death	457	26.26		569	19.33		0.73 (0.32, 1.67)	0.458	0.54 (0.24, 1.23)	0.144
Early neonatal death	457	24.07		569	15.82		0.65 (0.27, 1.59)	0.345	0.47 (0.20, 1.11)	0.086
Stillbirth	465	17.20		574	8.71		0.50 (0.16, 1.55)	0.230	0.46 (0.14, 1.54)	0.209
Perinatal death	465	40.86		574	24.39		0.59 (0.29, 1.18)	0.136	0.46 (0.23, 0.94)	0.034
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